Saturday, June 13, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 1063 of 1,261

  1. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  2. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  3. US 7354904

    Bacteriocin inducer peptides

    The United States of America, as represented by the Secretary of Agriculture · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  4. US 7354761

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    The Regents of the University of California · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  5. US 7354711

    Methods for inhibiting immunostimulatory DNA associated responses

    The Department of Veterans Affairs, as represented by the Secretary of United States of America · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  6. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  7. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  8. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  9. US 7354576

    Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase

    BIOMARIN PHARMACEUTICAL INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  10. US 7353829

    Methods and apparatus for multi-photon photo-activation of therapeutic agents

    Provectus Devicetech, Inc. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  11. US 7354900

    Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides

    The Board of Regents of the University of Oklahoma · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  12. US 7354894

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  13. US 7351739

    Bioactive compounds and methods of uses thereof

    Regents of the University of Minnesota · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  14. US 7351827

    Substituted oxetanes, method of making, and method of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  15. US 7351718

    Substituted pyrrolidine and related compounds

    Theravance, Inc. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  16. US 7351717

    Substituted pyrrolidine and related compounds

    Theravance, Inc. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  17. US 7351704

    Indazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance, Inc. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  18. US 7351542

    Methods of modulating tubulin deacetylase activity

    The Regents of the University of California · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  19. US 7351791

    Intermediate for preparing glycopeptide derivatives

    Theravance, Inc. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  20. US 7351691

    Glycopeptide phosphonate derivatives

    Theravance, Inc. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  21. US 7351411

    Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  22. US 7351408

    Glycoconjugates and methods

    The Regents of the University of California · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  23. US 7351403

    Sunscreen reagents from unsaturated waxes and triglycerides

    The United States of America, as represented by the Secretary of Agriculture · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

  24. US 7351435

    Deglycosylated ricin toxin a-chain vaccine

    The United States of America as represented by the Secretary of the Army · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.